Her2/neu Overexpression Is Associated with Treatment Failure in Women with High-Risk Stage II and Stage IIIA Breast Cancer (>10 Involved Lymph Nodes) Treated with High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support following Standard-Dose Adjuvant Chemotherapy

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1509-1513

  Bitran, Jacob D ^a   Samuels, Brian ^a   Trujillo, Yolanda ^a   Klein, Leonard ^a   Schroeder, Linda ^a   Martinec, James ^a  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROTO ONCOGENE; REMISSION; TREATMENT FAILURE; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 0030223058     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Eder, J. P., Antman, K., Peters, W., Henner, W. D., Elias, A., Shea, T., Schryber, S., Anderson, J., Come, S., Schnipper, L., and Frei, E., III. High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastalic breast cancer. J. Clin. Oncol., 4: 1592-1597, 1986
2. Williams, S. F., Mick, R., Desser, R., Golick, J., Beshorner, J., and Bitran, J. D. High dose consolidation therapy with autologous stem cell rescue in Stage IV breast cancer. J. Clin. Oncol., 7: 1824-1830, 1989.
3. Williams, S. F., Gilewski, T., Mick, R., and Bitran, J. D. High dose consolidation therapy with autologous stem cell rescue in Stage IV breast cancer: follow-up report. J. Clin. Oncol., 10: 1743-1747, 1992
4. Antman, K., Ayash, L., Elias, A., Wheeler, C., Hunt, M., Eder, J. P., Teicher, M. A., Critchlow, J., Bibbo, J., Schnipper, L. E., and Frei, E., III. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J. Clin. Oncol., 10: 102-110, 1992.
5. Bezwoda, W. R., Seymour, L., and Densey, R. D. High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer. A randomized trial. J. Clin. Oncol., 13: 2483-2489, 1995.
6. Peters, W. P., Ross, M., Vredenburgh, J. J , Meisenberg, B., Marks. R. B., Winer, E., Kurtzberg, J., Bast, R. C., Jr., Jones, R., Shpall, E. J., Wu, K., Rosner, G., Gilbert, C., Mathias, B., Coniglio, D., Petros, W., Henderson, I. C., Norton, L., Weiss, R. B., Budman, D., and Hurd, D. High dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high risk primary breast cancer. J. Clin. Oncol., 11: 1132-1143, 1993.
7. Peters, W. P , Berry, D., Vredenburgh, J. J., Hussein, A., Rubin, P , Elkordy, M., Ross, M., Hendersen, I. C., Budman, L., Norton, R., Weiss, R., and Hurd, D. Five year follow up of high dose combination alkylating agents with autologous bone marrow transplantation as consolidation after standard dose CAF for primary breast cancer involving ≥10 axillary lymph nodes (Duke/CALGB 8782). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 317, 1995.
8. Bitran, J. D., Samuels, B., Klein, L., Schroeder, L., Martinec, J., and Harris, E. Autologous bone marrow transplantation for women with stage II and IIA high risk (>10 involved lymph nodes). In: R. P. Gale, R. Champlin, and J. O Armitage (eds.), Breast Cancer, Blood Cell and Bone Marrow Transplants, p. 35 Keystone Symposium, Keystone, CO, 1996.
9. Bitran, J. D., Samuels, B., Klein, L., Hanauer, S., Johnson, L., Martinec, J , Harris, E., Kempler, J., and White, W. Tandem high dose chemotherapy supported by hematopoietic progenitor cells yield prolonged survival in stage IV breast cancer. Bone Marrow Transplant., 17: 157-162, 1996.
10. Grill, H J., Manz, B., and Pollow, K. Double labeling assay for estrogen and progestin receptors. Lancet, 6: 679-681, 1982.
11. Kallioniemi, O. P., Blanco, G., Alavarnko, M., Hietanen, T., Mattila, J , Lauslathi, K., Lehtinem, M., and Koivula, T. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. Cancer (Phila.), 62- 2183-2190, 1988.
12. Naber, S. P., Tsutsumi, Y., Yen, S., Zolnay, S. A., Motbaker, H., Marks, P. J., McKenzie, S. J., DeLellis, R. O , and Wolfe, H. J. Strategies for the analysis of oncogene overexpression: studies of neu oncogene in breast carcinomas. Am. J. Clin. Pathol., 94: 125-135, 1990.
13. Baak, J. P. A., Van Diest, P. J., Oritz, R., Matze-Cak, P., and Bacus, S. S. Comparative long term prognostic value of HER-2/neu protein expression, DNA ploidy and morphometric and clinical features in paraffin embedded invasive breast cancer. Lab. Invest., 64. 215-228, 1991.
14. Kaplan, E., and Meir, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
15. Dawson-Saunders, B., and Trapp, R. G. (eds). Basic and Clinical Biostatics. Ed. 2, p. 152. Norwalk, CT. Appleton and Lange, 1993
16. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ulrich, A., and McGuire, W. L. Human breast cancer, correlation of relapse and survival with amplification of Her-2/Neu oncogene. Science (Washington DC), 235: 177-182, 1987.
17. Lupu, R., Colomer, R., Kannan, B., and Lippman, M E. Characterization of a growth factor that binds exclusively to the erbB2 receptor and induces cellular responses. Proc. Natl Acad. Sci. USA, 89: 2287-2291, 1992.
18. Harris, A. L., Nicholson, S., Soenbury, R., Wright, C., and Farr, N. Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr. Natl. Cancer Inst., 11: 181-187, 1992.
19. Liu, E., Thor, A., He, M., Barcos, M., Ljung, B. M., and Benz, C. The HER-2/(c-erbB2) oncogene is frequently amplified in the in situ carcinomas of the breast. Oncogene, 7: 1027-1032, 1992.
20. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. O., Keith, P. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and McGuire, W. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
21. Tandon, A. K., Clark, G. M., Champness, G. C., Ullrich, A. L., and McGuire, W. L. Her-2/neu oncogene protein and prognosis in breast cancer J. Clin. Oncol., 7: 1120-1128, 1989.
22. O'Reilly, S. M., Barnes, D. M., Camplejohn, R. S., Bartkovav, Gregory W. M., and Richards, M. A. The relationship between C-erb-2 expression, S-phase traction and prognosis in breast cancer. Br. J. Cancer, 63: 444-446, 1991.
23. Paik, S., Hazan, R., Fisher, E. R., Sassi, R. F., Fisher, B., Redmond, C , Schlessinger, J., Lippman, M. F., and King, C. R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erb-2 protein overexpression in primary breast cancer. J. Clin. Oncol., 8: 102-112, 1990.
24. Clark, G. M., and McGuire, W. L. Follow up study of HER-2/neu amplification in primary breast cancer. Cancer Res., 51: 944-948, 1991.
25. Bonnadonna, G., and Valagussa, P. Dose response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med., 304: 10-15, 1981.
26. Wood, W. C., Budman, D. R., Kozum, A. H., Cooper, M. R., Younger, J., Hart, R., Moore, A., Ellerton, I. A., Norton, L., Ferree, C., Colangele-Ballow, A., Frei, G., III, and Henderson, I. C. Dose and dose intensity of adjuvant chemotherapy for stage II node positive breast cancer. N. Engl. J. Med., 330: 1253-1259, 1994.
27. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M , and Henderson, C. C-erbR2 expression and response to adjuvant therapy in women with node positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
28. Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abelott, M., Eudey, L., and McGuire, W. Her2/neu in node negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 599-605, 1992.
29. Gustuson, B. A., Geller, R. D., Goldhirsh, A., Price, K. N., Save-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Bürki, K., Castiglione, M., Collins, J., Lindtner, J., and Senn, H. J. Prognostic importance of c-erb-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
30. Gianni, A. M., Siena, S., Bregni, M., D., Nicola, M., Dodero, A., Zambetti, M., Orefice, S., Salvadori, B., Luin, A., Greco, M., Zucalii, R., Valagussa, P., and Bonnodonna, G. Five year results of high dose sequential adjuvant chemotherapy in breast cancer with ≥10 positive nodes. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 90, 1995.
31. Fay, J., Jones, S., Lynch, J., Herzig, R., Christiansen, N., Pitierio, L., Collins, R., Jr., Freeman, B., and Herzig, G. The treatment of primary breast cancer with intensive thiotepa, cyclophosphamide and hematopoietic stem cell transplantation: a phase II trial of the North American Marrow Transplant Group. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 104, 1995.
32. Somlo, G., Doroshow, J., Forman, S., Ahn, C., Leong, L., Margolin, K., Morgan, R., Raschkoiv, B., Jr., Baker, P., Rincoh, A., Chow, W., Akman, S., Shibat, S., Telef, M., Coluzzi, P., Molina, A., Nilanl, J Stein, A., Smith, E., and Yen, Y. High dose chemotherapy and stem cell rescue for the treatment of primary high risk breast cancer: prognostic indicators of overall survival and progression free survival. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 113, 1995.
33. Press, M. F. Oncogene amplification and expression: importance of methodological considerations Am. J. Clin. Pathol., 94: 240-241, 1990.
34. Makkink-Nombrado, S. V., Baak, J P., Schuurmans, L., Theeuwes, J. W., and van der Aa, T. Quantitative immunohistochemistry using the CAS200/486 image analysis system in invasive breast carcinoma: a reproducibility study. Anal. Cell. Pathol., 8: 227-245, 1995.
35. HER-2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
36. Pegram, M., Lipton, A., Pietras, R., Hayes, D., Weber, B., Baselga, J., Tripathy, D., Twadell, T., Gilaspy, J., and Salmm, D. Phase II study of intravenous recombinant humanized anti-p185 Her2/neu monoclonal antibody (rHu Mab HER-2) plus cisplatin in patients with Her2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 106, 1995.